Biomarin Pharmaceutical Inc (BMRN)

Return on assets (ROA)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	426,859	167,645	141,561	-64,080	854,029
Total assets	US$ in thousands	6,988,940	6,841,600	6,375,070	6,004,770	5,848,020
ROA		6.11%	2.45%	2.22%	-1.07%	14.60%

December 31, 2024 calculation

ROA = Net income ÷ Total assets
= $426,859K ÷ $6,988,940K
= 6.11%

Based on the provided data, Biomarin Pharmaceutical Inc's return on assets (ROA) has fluctuated over the past five years. In 2020, the ROA stood at a healthy 14.60%, indicating that the company generated $0.146 in profit for every dollar of assets it possessed.

However, by the end of 2021, the ROA sharply declined to -1.07%, suggesting that the company incurred a loss relative to its assets. This negative ROA may raise concerns about the company's operational efficiency or potential financial challenges during that period.

In the subsequent years, Biomarin's ROA showed signs of improvement, reaching 2.22% in 2022, 2.45% in 2023, and further climbing to 6.11% by the end of 2024. These positive trends indicate that the company has been more effective in generating profits from its assets over time, which can be a positive sign for investors and stakeholders.

Overall, while Biomarin Pharmaceutical Inc experienced a setback in 2021 with a negative ROA, the subsequent years showed a recovery and improvement in the company's ability to generate returns from its assets.